Once daily high dose tigecycline - pharmacokinetic/pharmacodynamic based dosing for optimal clinical effectiveness: dosing matters, revisited

Expert Review of Anti-infective Therapy
Burke A CunhaCheston B Cunha

Abstract

Tigecycline has emerged as first line therapy for serious systemic infections due to important pathogens (except P. aeruginosa and Proteus sp.), including multi-drug resistant (MDR) and Gram negative bacilli (GNB), including carbapenem resistant Enterobacteriae. Tigecycline has a 'low resistance potential,' is protective against C. difficile, and is often the only antibiotic effective against MDR GNB, e.g., Klebsiella sp. Areas covered: Standard dose tigecycline therapy has been used for intra-abdominal infections, complicated skin/skin structure infections (cSSSIs), and CAP. Clinical experience with once daily high dose tigecycline (HDT), i.e., 200 - 400 mg (IV) x 1, then 100 - 200 mg (IV) q24 h, is reviewed. Optimal tigecycline efficacy is dependent on PK/PD based dosing. Suboptimal outcomes have been due to inappropriate use or suboptimal dosing. Expert commentary: Tigecycline's spectrum against nearly all important pathogens (including MSSA/MRSA, VSE/VRE, B. fragilis, C. difficile, MDR and GNB) assures tigecycline a critical place in the antibiotic armamentarium. Dosed optimally, HDT can be a cornerstone of antibiotic stewardship programs in preventing C. difficile, treating MDR GNB pathogens, and in preventing resistance. ...Continue Reading

References

Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B A CunhaC B Cunha
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·Gopal MuralidharanSteven Troy
May 12, 2005·International Journal of Antimicrobial Agents·John E ConteElisabeth Zurlinden
Jul 26, 2005·The Journal of Antimicrobial Chemotherapy·George A Pankey
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison K MeagherEvelyn J Ellis-Grosse
Aug 18, 2005·Diagnostic Microbiology and Infectious Disease·Lance R Peterson
Aug 18, 2005·Diagnostic Microbiology and Infectious Disease·Samuel K BouchillonUNKNOWN Tigecycline Evaluation and Surveillance Trial (TEST) Group
Aug 27, 2005·The Journal of Antimicrobial Chemotherapy·David M Livermore
Jun 23, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Nishaminy Kasbekar
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary E Stein, William A Craig
Sep 20, 2006·Clinical Therapeutics·Thien-Ly DoanPaul F Riska
Jan 19, 2007·The Journal of Antimicrobial Chemotherapy·Neil WoodfordDavid M Livermore
Apr 26, 2008·The Journal of Antimicrobial Chemotherapy·Drosos E KarageorgopoulosMatthew E Falagas
Aug 14, 2008·The Journal of Antimicrobial Chemotherapy·Alasdair P MacGowan
Oct 14, 2008·Expert Review of Anti-infective Therapy·Jason J Schafer, Debra A Goff
Mar 13, 2009·International Journal of Antimicrobial Agents·Olaf BurkhardtTobias Welte
Apr 7, 2009·The Journal of Infection·Garyphallia PoulakouHelen Giamarellou
Feb 25, 2010·The Annals of Pharmacotherapy·Leslie RayMarc H Scheetz
May 14, 2010·International Journal of Antimicrobial Agents·D SevillanoJ Prieto
Oct 12, 2010·The Journal of Antimicrobial Chemotherapy·R HopeUNKNOWN Tigecycline Susceptibility Testing Group
Apr 8, 2011·The Medical Journal of Australia·Elaine Y L Cheong, Thomas Gottlieb
Apr 3, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paritosh PrasadCharles Natanson
Nov 17, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Francesco SbranaFrancesco Menichetti
Nov 20, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Jiao XieYalin Dong
Dec 21, 2013·Scandinavian Journal of Infectious Diseases·B Balandin MorenoP Galdos Anuncibay
Jun 3, 2014·Critical Care : the Official Journal of the Critical Care Forum·Gennaro De PascaleMassimo Antonelli
Jul 2, 2014·Case Reports in Medicine·Dilip DanVijay Naraynsingh
Jul 22, 2014·Critical Care : the Official Journal of the Critical Care Forum·José Garnacho-Montero, Carmen Ferrándiz-Millón
Jul 30, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ashley ThomasMark R Wallace
Dec 3, 2014·International Journal of Antimicrobial Agents·Chien-Wen HuangChao-Tsai Liao
Feb 25, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B A Cunha
Sep 19, 2015·Current Opinion in Infectious Diseases·Suzanne L ParkerJason A Roberts

❮ Previous
Next ❯

Citations

Nov 22, 2017·Antimicrobial Agents and Chemotherapy·Ana Carolina RamosAna Cristina Gales
Oct 18, 2019·Expert Review of Anti-infective Therapy·Philippe MontraversAlexy Tran-Dinh
Jul 11, 2020·Journal of Clinical Pharmacy and Therapeutics·Weijin FangChunjiang Wang
Jul 25, 2019·International Journal of Molecular Sciences·Zhen DongHongjuan Cui
Jul 15, 2020·Annals of Intensive Care·Gennaro De PascaleMassimo Antonelli
Oct 4, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Rajeev SomanBalaji Veeraraghavan
Mar 25, 2021·Revista Da Sociedade Brasileira De Medicina Tropical·Elizabeth Maria Bispo BeltrãoAna Catarina de Souza Lopes
Nov 6, 2018·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Andrei Nicoli Gebieluca DabulIlana Lopes Baratella da Cunha Camargo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.